CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Maddocks: So let ...

Optimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large prospective cohort study to identify current demographics and patterns of care of FL in the United States. Two thousand ...

More than 138.3 million people are known to have contracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, with over 2.9 million deaths. Jerusalem, in Israel, is a city that ...

—What’s the next step for this patient with a 4-year history of low-grade follicular lymphoma and who now has worsening lymphadenopathy and needs a nap at the end of every work day? A 58-year-old male ...

Lower socioeconomic status is associated with poor survival in lymphoma. Patients with follicular lymphoma (FL) lived longer if they had private insurance, according to a study that examined patient ...

We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy. We randomly ...

SAN DIEGO — Subcutaneous time-limited mosunetuzumab exhibited “highly encouraging efficacy” among patients with newly diagnosed high-burden follicular lymphoma, according to researchers. Perspective ...

Researchers from Memorial Sloan Kettering Cancer Center (MSK) announced today that the latest results from that follicular lymphoma clinical trial have shown the three-drug combination — rituximab ...

Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision ...